Alnylam Pharmaceuticals Dividend yield

 Price  141.19
 Dividend  0.00
 Earnings  -7.35
 Cash-flow  -5.31
 Book value  8.77
 Equity  10.56

Alnylam Pharmaceuticals is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Alnylam Pharmaceuticals is a company from USA, and his stocks are publicly traded.

Alnylam Pharmaceuticals paid a total dividend of 0 million USD last year, for a market value of 16,378 millions (Market Cap 16,243 millions). Dividend per share of Alnylam Pharmaceuticals is 0.00 USD, and his stock market price 141.19 USD.

According to the chart below where dividend yield is displayed, Alnylam Pharmaceuticals, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from USA, Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of Alnylam Pharmaceuticals might harm the evolution of share price if the company is not clearly expanding his business.

In addition, you should compare Alnylam Pharmaceuticals dividend yield with other Pharmaceuticals and Biotechnology companies or firms from USA.

Dividend yield of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Dividend Payout

About the ability of Alnylam Pharmaceuticals to maintain his current dividend of USD 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Alnylam Pharmaceuticals payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.

The following figure shows payout ratios over earnings and cashflow of Alnylam Pharmaceuticals, compared againt world market average, USA companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

Alnylam Pharmaceuticals payout

Alnylam Pharmaceuticals Dividend History

Year Yield  USD  Paypout  Shares* 

*In millions

Alnylam Pharmaceuticals Stock performance

Finally, last moth Alnylam Pharmaceuticals showed a return of -4.70% compared to a worldwide 4.24% average, and a 3.00% of Health Care firms. Over the last year, the company obtained a 29.70% versus a worldwide performance of a 53.49%. More detailed information can be seen in the following graph for USA and Pharmaceuticals and Biotechnology firms.

Alnylam Pharmaceuticals stock and market return